Regeneron backed Parabilis seeks U.S. IPO (PBLS:Pending)
· seekingalpha.com
Regeneron (REGN) stock is in focus as the company's newly found research partner, Parabilis Medicines (PBLS), files for an IPO on Nasdaq. Read more here.
Soon after reaching a research pact worth up to $2.3B with Regeneron (REGN), clinical-stage biopharma Parabilis Medicines (PBLS) has submitted regulatory filing...